Drugs / NP10679
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04007263 | Apr → Aug 2019 | ischemic stroke, neuropathy, painful, subarachnoid hemorrhage, substance abuse | Neurop Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03565861 | Apr → Sep 2018 | — | Neurop Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP10679 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04007263 ↗ |
| Action | Inhibit | “NP10679 is a pH dependent inhibitor of the GluN2B subtype of the NMDA receptor.” NCT03565861 ↗ |
| Modality | Small molecule | — CHEMBL5095254 ↗ |
| Route | Intravenous | “when delivered intravenously in up to six escalating dose levels” NCT03565861 ↗ |